Heart Failure News and Research RSS Feed - Heart Failure News and Research

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.
Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

Boston Scientific announces the signing of two strategic agreements to advance the company's efforts to bring value based solutions aimed at improving outcomes and reducing the cost of cardiovascular care delivery to healthcare systems. [More]

HeartWare International's revenue increases 5% to $70.0 million in first quarter 2015

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $70.0 million for the first quarter ended March 31, 2015, a five percent increase compared to $66.5 million in revenue for the same period of 2014. [More]
Study finds that gene therapy can clip out genetic material associated with heart failure

Study finds that gene therapy can clip out genetic material associated with heart failure

Gene therapy can clip out genetic material linked to heart failure and replace it with the normal gene in human cardiac cells, according to a study led by researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai. [More]
Global market for cardiac rhythm management devices worth $13 billion for 2015

Global market for cardiac rhythm management devices worth $13 billion for 2015

The global market for cardiac rhythm management devices such as pacemakers and defibrillators is worth about $13 billion for 2015, according to Kalorama Information. The market research publisher said the market has benefited from the demand to move to a more mobile, wireless and efficient system both within major health facilities and in the home treatment markets. There is also an increasing trend to upgrade to more portable devices and devices which have added benefits such as MRI compatibility. [More]
Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death. [More]
Mount Sinai, par8o create referral platform for Health System's care providers

Mount Sinai, par8o create referral platform for Health System's care providers

The Mount Sinai Health System and software company par8o are creating a seamless referral process for the Health System's care providers. [More]
Study explores how NYC doctor can perform tele-robotic ultrasound over the Internet on patients in Chicago

Study explores how NYC doctor can perform tele-robotic ultrasound over the Internet on patients in Chicago

A new clinical trial is testing the feasibility and efficiency of a doctor in New York City remotely performing long-distance, tele-robotic ultrasound exams over the Internet on patients in Chicago. [More]
Findings could help design tailor-made drugs to treat blood pressure

Findings could help design tailor-made drugs to treat blood pressure

One in three Americans has high blood pressure, a long-term constriction of arteries that can lead to coronary heart disease, heart failure and stroke. [More]
Record number of abstracts submitted to Heart Failure 2015

Record number of abstracts submitted to Heart Failure 2015

A record number of abstracts have been submitted to the world's leading heart failure congress, promising more original science than ever before. [More]
WPI researchers receive NIH grant to develop new class of tissue-engineered heart valves

WPI researchers receive NIH grant to develop new class of tissue-engineered heart valves

With a $450,000 grant from the National Institutes of Health, researchers at Worcester Polytechnic Institute will analyze how mechanical forces and cellular growth factors affect the growth and development of human heart valves to advance the long-term goal of using tissue engineering to develop replacement valves that are more natural and longer-lasting than current replacement valves. [More]
IUPUI researcher awarded NIH grant to study neuroscience underlying obstructive sleep apnea

IUPUI researcher awarded NIH grant to study neuroscience underlying obstructive sleep apnea

Sleep apnea affects an estimated 25 million adults in the United States and is associated with increased risk of hypertension, stroke, health attack and heart failure. [More]
MGH researchers find probable mechanism associated with risk of developing serious diseases

MGH researchers find probable mechanism associated with risk of developing serious diseases

Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications. In a paper published in the American Journal of Hematology, the research team reports finding that higher levels of a measure routinely taken as part of the complete blood count - the extent of variation in the size of red blood cells - is caused by reduced clearance of aging cells from the bloodstream. [More]
Pulmonary Hypertension Center at RI Hospital receives PHA accreditation

Pulmonary Hypertension Center at RI Hospital receives PHA accreditation

The Pulmonary Hypertension Center at Rhode Island Hospital is one of the nation's first centers of its kind to be accredited by the Pulmonary Hypertension Association. For those affected by pulmonary hypertension (PH), accreditation assures them and their providers that they have access to the most advanced care available in the country. [More]
CiRA, Takeda collaborate to develop clinical applications of iPS cells

CiRA, Takeda collaborate to develop clinical applications of iPS cells

Center for iPS Cell Research Application of Kyoto University and Takeda Pharmaceutical Company Limited announced today that they will work together to develop clinical applications of induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy. [More]
HeartWare Ventricular Assist System meets primary endpoint in ENDURANCE clinical trial

HeartWare Ventricular Assist System meets primary endpoint in ENDURANCE clinical trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its first destination therapy clinical trial cohort, ENDURANCE, successfully demonstrated that the trial achieved the primary endpoint. [More]
Ancient natural compound can protect the heart from hypertrophy

Ancient natural compound can protect the heart from hypertrophy

A natural compound derived from the bark of the magnolia tree, can protect the heart from hypertrophy, a thickening of cardiac muscle often caused by chronic high blood pressure that can lead to heart failure, researchers report in the April 14 issue of the online journal Nature Communications. [More]
Early decline in 6MWT distance predicts PAH worsening

Early decline in 6MWT distance predicts PAH worsening

Research shows that an early decline in 6-minute walk test distance can predict worsening of disease in patients with pulmonary arterial hypertension. [More]
Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 can be used to distinguish idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction, research indicates. [More]
Latest findings regarding nitric oxide offer new avenues to save lives

Latest findings regarding nitric oxide offer new avenues to save lives

Professor Jonathan Stamler's latest findings regarding nitric oxide have the potential to reshape fundamentally the way we think about the respiratory system - and offer new avenues to save lives. It may be time to rewrite the textbooks. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]
Advertisement